Information Provided By:
Fly News Breaks for November 18, 2019
Nov 18, 2019 | 06:26 EDT
Citi analyst Joel Beatty lowered his price target for Sarepta Therapeutics (SRPT) to $167 from $180 saying the company's earnings "were incrementally negative." However, any losses were offset by the recent Solid Biosciences (SLDB) news, which is a positive for Sarepta, Beatty tells investors in a research note. The analyst keeps a Buy rating on Sarepta as he sees the company "winning the race to market" for the Duchenne muscular dystrophy gene therapies.
News For SRPT;SLDB From the Last 2 Days
There are no results for your query SRPT;SLDB